Literature DB >> 12930149

Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases.

Cassandra L Woodard1, Zhiyu Li, April K Kathcart, James Terrell, Lucia Gerena, Miriam Lopez-Sanchez, Dennis E Kyle, Apurba K Bhattacharjee, Daniel A Nichols, William Ellis, Sean T Prigge, Jeanne A Geyer, Norman C Waters.   

Abstract

Cyclin dependent protein kinases (CDKs) have become attractive drug targets in an effort to identify effective inhibitors of the parasite Plasmodium falciparum, the causative agent of the most severe form of human malaria. We tested known CDK inhibitors for their ability to inhibit two malarial CDKs: Pfmrk and PfPK5. Many broad spectrum CDK inhibitors failed to inhibit Pfmrk suggesting that the active site differs from other CDKs in important ways. By screening compounds in the Walter Reed chemical database, we identified oxindole-based compounds as effective inhibitors of Pfmrk (IC(50) = 1.5 microM). These compounds have low cross-reactivity against PfPK5 and human CDK1 demonstrating selectivity for Pfmrk. Amino acid comparison of the active sites of Pfmrk and PfPK5 identified unique amino acid differences that may explain this selectivity and be exploited for further drug development efforts.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12930149     DOI: 10.1021/jm0300983

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

Review 1.  Regulation of DNA replication proteins in parasitic protozoans: possible role of CDK-like kinases.

Authors:  Abhijit S Deshmukh; Meetu Agarwal; Suman Kumar Dhar
Journal:  Curr Genet       Date:  2016-01-16       Impact factor: 3.886

2.  Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.

Authors:  Cornelius Klöck; Xi Jin; Kihang Choi; Chaitan Khosla; Peter B Madrid; Andrew Spencer; Brian C Raimundo; Paul Boardman; Guido Lanza; John H Griffin
Journal:  Bioorg Med Chem Lett       Date:  2010-12-16       Impact factor: 2.823

3.  Stereochemical evaluation of bis(phosphine) copper catalysts for the asymmetric alkylation of 3-bromooxindoles with α-arylated malonate esters.

Authors:  Chung Whan Lee; Seo-Jung Han; Scott C Virgil; Brian M Stoltz
Journal:  Tetrahedron       Date:  2015-06-03       Impact factor: 2.457

4.  Correlation between Cyclin Dependent Kinases and Artemisinin-Induced Dormancy in Plasmodium falciparum In Vitro.

Authors:  Karen-Ann Gray; Karryn J Gresty; Nanhua Chen; Veronica Zhang; Clare E Gutteridge; Christopher L Peatey; Marina Chavchich; Norman C Waters; Qin Cheng
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

5.  Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, are new anti-malarial agents.

Authors:  Sandrine Houzé; Nha-Thu Hoang; Olivier Lozach; Jacques Le Bras; Laurent Meijer; Hervé Galons; Luc Demange
Journal:  Molecules       Date:  2014-09-23       Impact factor: 4.411

6.  Synthesis and antibacterial activity studies in vitro of indirubin-3'-monoximes.

Authors:  Fen-Fen Yang; Ming-Shan Shuai; Xiang Guan; Mao Zhang; Qing-Qing Zhang; Xiao-Zhong Fu; Zong-Qin Li; Da-Peng Wang; Meng Zhou; Yuan-Yong Yang; Ting Liu; Bin He; Yong-Long Zhao
Journal:  RSC Adv       Date:  2022-09-02       Impact factor: 4.036

7.  The use of minimal topological differences to inspire the design of novel tetrahydroisoquinoline analogues with antimalarial activity.

Authors:  Joelleinsert Ngo Hanna; Vincent de Paul N Nziko; Fidele Ntie-Kang; James A Mbah; Flavien A A Toze
Journal:  Heliyon       Date:  2021-05-21

8.  Plasmodial Kinase Inhibitors: License to Cure?

Authors:  Diego González Cabrera; André Horatscheck; Colin R Wilson; Greg Basarab; Charles J Eyermann; Kelly Chibale
Journal:  J Med Chem       Date:  2018-06-04       Impact factor: 7.446

Review 9.  An Update on Development of Small-Molecule Plasmodial Kinase Inhibitors.

Authors:  Chantalle Moolman; Rencia van der Sluis; Richard M Beteck; Lesetja J Legoabe
Journal:  Molecules       Date:  2020-11-07       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.